- Home
- ZIP vs OBIO Comparison
ZIP vs OBIO Comparison
Compare ZIP & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZIP | OBIO |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.9M | 246.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZIP | OBIO |
|---|---|---|
| Price | $2.44 | $4.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $3.88 | ★ $14.25 |
| AVG Volume (30 Days) | ★ 1.2M | 165.7K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $448,952,000.00 | $33,482,000.00 |
| Revenue This Year | $1.00 | N/A |
| Revenue Next Year | $5.93 | $12.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $1.65 | $2.20 |
| 52 Week High | $6.55 | $5.42 |
Technical Indicators
Market Signals| Indicator | ZIP | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 55.74 |
| Support Level | $1.68 | $4.02 |
| Resistance Level | $2.59 | $4.88 |
| Average True Range (ATR) | 0.19 | 0.24 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 98.03 | 59.49 |
Price Performance
Historical ComparisonAbout ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace that connects job seekers and employers through an AI-powered platform. The company provides recruiting solutions that help employers identify and hire qualified candidates while enabling job seekers to discover relevant job opportunities through intelligent matching and recommendation tools.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.